Vimarsana
Biggest News Aggregation in the World

Page 22 - Presentation Details News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Presentation Details. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Presentation Details Today - Breaking & Trending Today

Immunitas Therapeutics to Present Preclinical Data on IMT-009 at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting - Vimarsana News

Immunitas Therapeutics to Present Preclinical Data on IMT-009 at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

/PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a precision immunotherapy company committed to discovering and developing novel, differentiated...

Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting - Vimarsana News

Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting

/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today...

SpringWorks Therapeutics Announces Data from Phase 3 DeFi - Vimarsana News

SpringWorks Therapeutics Announces Data from Phase 3 DeFi

– Nirogacestat Treatment Resulted in Rapid, Sustained and Statistically Significant Improvements in Primary and All Key Secondary Efficacy Endpoints – –...

NRx Pharmaceuticals Leaders to Present at the H.C. Wainwright & Co. 24th Annual Global Investment Conference - Vimarsana News

NRx Pharmaceuticals Leaders to Present at the H.C. Wainwright & Co. 24th Annual Global Investment Conference

/PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, today announced its Chief Executive Officer, Stephen...

Lyra Therapeutics to Present Additional LANTERN Phase 2 Study Results for LYR‑210 in Two Oral Presentations at ARS Annual Meeting - Vimarsana News

Lyra Therapeutics to Present Additional LANTERN Phase 2 Study Results for LYR‑210 in Two Oral Presentations at ARS Annual Meeting

/PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise,...